CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics
CytomX Therapeutics, Inc. (CTMX)
Today's Latest Price: $7.42 USD
0.11 (-1.46%)
Updated Dec 2 4:00pm
Add CTMX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CTMX Stock Summary
- Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.3% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for CytomX Therapeutics Inc is higher than it is for about just 14.36% of US stocks.
- As for revenue growth, note that CTMX's revenue has grown 52.05% over the past 12 months; that beats the revenue growth of 90.13% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CytomX Therapeutics Inc are WVE, CRBP, MTEM, PIRS, and NTLA.
- Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.
CTMX Stock Price Chart Interactive Chart >
CTMX Price/Volume Stats
| Current price | $7.42 | 52-week high | $15.44 |
| Prev. close | $7.53 | 52-week low | $3.60 |
| Day low | $7.32 | Volume | 616,100 |
| Day high | $7.52 | Avg. volume | 498,833 |
| 50-day MA | $6.98 | Dividend yield | N/A |
| 200-day MA | $7.75 | Market Cap | 342.98M |
CytomX Therapeutics, Inc. (CTMX) Company Bio
CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.
Loading social stream, please wait...